One Year Follow-ups of Patients Admitted to Spanish Intensive Care Units Due to COVID-19
Launched by CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (CIBER) · Jul 2, 2020
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
Objective and Purpose of Study
1. The main objective is to determine risks factors and prognosis of patients with COVID-19 infection who have been admitted to Spanish ICUs between the beginning and end of the pandemic in Spain. Special attention will be placed on identifying differential expression of prognostic factors based on sex.
2. The second objective is to perform a follow-up of patients within 6 months after discharge from ICU and hospital in order to determine mortality (including at 1-year mark), functional respiratory and cardiovascular consequences, and quality of life.
3. The ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Laboratory-confirmed COVID-19 infection with either real-time PCR or Next Generation Sequencing (NGS)
- • 2. Admission to intensive care unit
- Exclusion Criteria:
- • 1. Patients admitted to COVID-19-negative ICU
About Consorcio Centro De Investigación Biomédica En Red (Ciber)
The Consorcio Centro de Investigación Biomédica en Red (CIBER) is a collaborative network dedicated to advancing biomedical research in Spain. Established to enhance scientific knowledge and innovation, CIBER integrates top-tier research centers, universities, and healthcare institutions, fostering interdisciplinary collaboration and promoting the translation of research findings into clinical practice. By focusing on key health challenges, CIBER aims to accelerate the development of new therapies and improve patient outcomes, while also contributing to the training of researchers and the dissemination of scientific knowledge across the biomedical field.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Barcelona, , Spain
Hospitalet De Llobregat, Barcelona, Spain
Pontevedra, , Spain
Barcelona, , Spain
Barcelona, , Spain
Mataró, Barcelona, Spain
Tarragona, , Spain
León, , Spain
Valencia, , Spain
Cáceres, , Spain
Palma De Mallorca, Mallorca, Spain
Salamanca, , Spain
Tortosa, Tarragona, Spain
Ourense, , Spain
Valencia, , Spain
Lugo, Galicia, Spain
Palencia, , Spain
Vigo, Pontevedra, Spain
Oviedo, Asturias, Spain
Sant Cugat Del Vallès, Barcelona, Spain
Cabra, Córdoba, Spain
Alicante, , Spain
Barcelona, , Spain
Barcelona, , Spain
Burgos, , Spain
Lleida, , Spain
Madrid, , Spain
Sevilla, , Spain
Valladolid, , Spain
Zaragoza, , Spain
Patients applied
Trial Officials
Antoni Torres, PhD
Principal Investigator
Spanish Research Center for Respiratory Diseases
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials